Fenretinide
Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
Explore 16 assets in Nodal T-Follicular Helper Cell Lymphoma, Follicular Type →Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
SciTech Development, Inc.
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04234048CT.gov Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nodal T-Follicular Helper Cell Lymphoma, Follicular Type
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fenretinide (this asset) | SciTech Development, Inc. | P1 | CC · 43 |
| Pralatrexate | Corvus Pharmaceuticals, Inc. | P3 | BB |
| Nivestim | City of Hope Medical Center | P3 | B |
| Soquelitinib | Corvus Pharmaceuticals, Inc. | P3 | B |
| Pembrolizumab | Northwestern University | P2 | B |
| Cyclophosphamide | City of Hope Medical Center | P2 | B |
| Adriamycin | City of Hope Medical Center | P2 | B |
| Prednisone | City of Hope Medical Center | P2 | B |
| Belinostat | Corvus Pharmaceuticals, Inc. | P3 | B |
+10 more in the Nodal T-Follicular Helper Cell Lymphoma, Follicular Type cohort
Other indications for Fenretinide
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Peritoneal Carcinoma | — | P2 | B · 58 |
| Cancer | — | P3 | B · 56 |
| Cognitive Disorder | — | P3 | B · 56 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fenretinide in Nodal T-Follicular Helper Cell Lymphoma, Follicular Type. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fenretinide-nodal-t-follicular-helper-cell-lymphoma-follicular-type
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →